The only FDA-approved GHRH peptide. It does not give you HGH. It asks your pituitary to release growth hormone the way it did when you were thirty — and the visceral fat responds first.
Tesamorelin is a 44-amino-acid analog of growth hormone–releasing hormone (GHRH). Instead of injecting growth hormone directly, it stimulates your pituitary to release its own GH in physiologic pulses — the same architecture your endocrine system uses naturally. The downstream IGF-1 response is real, but the regulatory feedback loops your body uses to prevent excess GH stay intact.
This is the cleaner answer to the question most patients in their forties and fifties are actually asking: "Can I get the metabolic effects of growth hormone without the risks of injecting it?" For most people, yes — and tesamorelin is the clearest path there. It is FDA-approved for HIV-associated lipodystrophy, the only GHRH analog with that status, and the off-label evidence in non-HIV visceral adiposity is strong and growing.
Pooled clinical-trial data, GHRH analog vs. placebo, abdominal-fat-accumulation populations.
Across the major trials, a "responder" was defined as a patient losing at least 8% of visceral adipose tissue (VAT) by imaging. Roughly 70% of tesamorelin-treated participants met that bar. That is a high response rate for a metabolic intervention — comparable to or exceeding GLP-1s for visceral compartment specifically, which is the compartment most causally linked to cardiometabolic risk.
A 2026 pooled meta-analysis of five randomized controlled trials reports a mean reduction of −27.7 cm² in VAT and an increase of +1.42 kg in lean body mass. ART-era data published since show roughly 5% lower hepatic fat versus placebo, with concurrent improvement in triglycerides and CRP. The lean-mass preservation is a key advantage over GLP-1 monotherapy, where lean-mass loss remains a documented concern.
Read the evidence → Physician summary of the 2026 pooled meta-analysis (5 trials, n=816)
One of the more interesting findings: tesamorelin's effect is selective. The fat under your skin — the kind you can pinch — does not meaningfully change. It is the deep, organ-encasing fat that responds. For patients who do not need cosmetic weight loss but do need to clear the visceral compartment driving their insulin resistance and inflammation, this is the right tool.
A 2021 study (Adrian et al., revisited in 2026 reviews) demonstrated that tesamorelin improves liver fat density and the metabolic profile of remaining adipose tissue beyond what is explained by mass loss alone. In other words: less fat and healthier fat. That has implications for NAFLD, ALT/AST normalization, and long-term cardiometabolic risk.
Branded tesamorelin (Egrifta) costs roughly $4,000–6,000 per month at retail. Compounded tesamorelin from a licensed 503A pharmacy is a fraction of that — and is now legally prepared following the April 23, 2026 reclassification, pending the July 23–24 PCAC formal review. We use 503A-compounded tesamorelin for off-label visceral-adiposity protocols and disclose this clearly in informed consent.
The original Phase III trials predated integrase-inhibitor (INSTI) antiretroviral therapy, which is now the standard of care. A 2026 randomized double-blind trial of 61 patients on INSTI-based regimens evaluated tesamorelin 2 mg daily versus placebo at 12 months. The result: a median 16% reduction in visceral fat cross-sectional area, comparable to the 15–18% effect size seen in the original trials. Roughly two-thirds of treated participants achieved a clinically significant VAT reduction, while the placebo group gained visceral fat. Glycemic control was unchanged. The trial puts to rest the open question of whether tesamorelin's efficacy holds up on modern HIV regimens — and, by extension, reinforces confidence in its use as an off-label visceral-adiposity tool in metabolically similar (non-HIV) patients selected on the same physiologic basis.
This is the most underappreciated finding of the last two years. Tesamorelin restores the GHRH pulse that flattens with aging, and that pulse drives downstream IGF-1 signaling in the hippocampus and prefrontal cortex. A 2024–2026 series of trials in adults with subjective cognitive impairment — including HIV-associated and age-related — has reported measurable improvements in executive function, working memory, and processing speed after 20–26 weeks of standard 2 mg dosing. Effect sizes are modest but real, and they appear independent of the body-composition changes. The clinical implication: tesamorelin is no longer just a body-recomposition tool. It is an emerging candidate for the rare class of "systemic optimizers" that move both metabolic and cognitive endpoints in the same direction. We do not promise cognitive benefit to patients selecting tesamorelin for visceral fat; we do disclose it as a credible secondary endpoint and track it informally with the Limitless cognitive screen at baseline and 26 weeks.
Injected into abdominal subcutaneous tissue, rotating sites. Bedtime timing aligns the pulse with natural overnight GH release. Most patients tolerate without symptoms.
For patients with sensitivity to GH-axis stimulation (transient joint discomfort, water retention) or impaired glucose tolerance — slower titration improves tolerability without sacrificing efficacy.
We run a 26-week course, then pause for a 4-week washout, reassess imaging or anthropometrics, and decide on continuation, dose reduction (1 mg maintenance), or completion. Indefinite daily dosing is not the default.
Baseline IGF-1, fasting glucose/insulin, HbA1c, lipid panel, comprehensive metabolic panel, waist circumference, optional DEXA for VAT quantification. Repeated at 12 and 26 weeks. We hold or reduce dose if IGF-1 exceeds the upper third of age-adjusted reference, fasting glucose climbs > 110, or HbA1c rises > 0.4 from baseline.
| Tesamorelin (GHRH) | Exogenous HGH | |
|---|---|---|
| Mechanism | Stimulates pituitary to release endogenous GH in pulses | Direct injection of recombinant GH |
| Endogenous feedback intact? | Yes — GH continues to respond to somatostatin | No — bypasses the regulatory loop |
| FDA approval | Yes (HIV-associated lipodystrophy) | Yes — but only for narrow indications (GH deficiency, short stature, AIDS wasting). "Anti-aging" use is not approved and not legal in most contexts. |
| Insulin resistance risk | Modest, monitorable — held if fasting glucose climbs | Higher — sustained supraphysiologic GH drives IR more aggressively |
| IGF-1 ceiling effect | Self-limiting via somatostatin feedback | Dose-dependent, can drive IGF-1 well above physiologic range |
| Compounded availability (post-Apr 23, 2026) | Yes, via licensed 503A/503B | Compounding of HGH for non-approved indications is not legal |
| Visceral fat selectivity | High — VAT responds, SAT mostly preserved | Less selective; broader body-comp shifts |
| Limitless protocol? | Yes — for indicated patients | No — we do not prescribe exogenous HGH for non-approved indications |
This is the central reason tesamorelin is on the Limitless menu and exogenous HGH is not. The mechanism is cleaner, the regulatory posture is defensible, and the visceral-fat outcome — the one that actually matters for cardiometabolic longevity — is at least as good.
Modestly, but tesamorelin's signature effect is on visceral fat. If your goal is to lose ten pounds you can see in the mirror, tesamorelin is the wrong tool — a GLP-1 protocol or body-composition approach is better. If your goal is to clear the deep fat that drives insulin resistance, lipid abnormalities, and fatty liver, tesamorelin is among the best tools we have.
Yes. The mechanisms are complementary — tesamorelin shifts visceral fat through GH-axis stimulation; GLP-1s reduce overall caloric intake and broader adiposity. We sequence them carefully and watch IGF-1, glucose, and lean-mass markers closely.
Sleep and recovery quality often shift first, within 2–4 weeks. Waist circumference begins to move at 8–12 weeks. Imaging changes are clearest at 26 weeks. We do not advise judging the protocol on early scale weight.
That is the desired effect — within physiologic range. We hold or reduce dose if IGF-1 climbs into the upper third of age-adjusted reference, and we screen carefully for any IGF-1-sensitive concerns at baseline.
Long-term safety data outside the HIV-lipodystrophy population is still incomplete. We use 26-week courses with reassessment rather than indefinite daily dosing for that reason. The known safety profile is favorable; the unknown is what drives our cycling protocol.
A 30-minute consultation, baseline labs (including IGF-1, metabolic, and optional DEXA), and a written 26-week protocol — sourced, prescribed, and monitored to a documented standard.
Book a Consultation